Abstract:HIV-1 gp41-like human type I interferon (IFN) could inhibit lymphocyte proliferation and up-modulate MHC class I and II and ICAM-1 molecule expression. Sequence comparison indicates that asimil are pitope RILAV-YLKD exists between N-domain of gp41 and two regions in IFN-α (aa29–35 and 113–129), IFN-β (aa31–37 and 125–138) and IFN-ω(aa29–35 and 123–136), which was shown to form IFN-α/β-receptor binding site. Weak sequence similarity was also found to exist in both regionson gp41 and type I IFN of murine and bovine. Experimental studies, indicated that acommon immunological epitope exists between gp41 and IFN-α and β. Antibodies sagainst human IFN-α and-β recognized the common immunological epitope and inhibited gp41-binding to the potential cellular receptor protein p45. Moreover, the polyclonal antibody to IFN-β completely inhibited gp41-binding to human T, B cells and monocytic cells, while IFN-α could only inhibit this binding incompletely. It was interestingly observed that human IFN-β after preincubating with cells could incompletely inhibit the binding of gp41 to human B cells and monocytic cells, and very weakly inhibit the binding to human T cells, indicating, that the receptor for IFN-β-binding may be, involved in, gp41 binding. This potential relationship may be based on the amino acid sequence homology in the receptor binding region between gp41 and IFN-β. It was observed that the increased levels of antibodies againsthuman IFN-α and-β exist in HIV-1-infected individuals and are associated with the common epitope on gp41. Besides, several studies provided experimental evidence that the common immunological epitope could induce protective activity against HIV-1. The IFN-α-based vaccine has showed a significant reduction of disease progression in IFN-α-vaccine-treated HIV-infected patients. Recent experimental evidence indicates that gp41 and IFN-β were involved in downregulation of CCR5 expression and induction of cells activation or signal transduction. Whe ther it may be performed by a similar mechanism, is still to be investigated.

Progress in the structure and function of human immunodeficiency virus type 1 gp41

The Structural and Functional Researches of HIV-1 Gp41 NC Six-Helix-bundle

N- and C-domains of HIV-1 gp41: mutation, structure and functions.

Biological Function of H1V-1 Transmembrane Protein Gp41

Biological Function Of Hiv-1 Transmembrane Protein Gp41 - A Study On A Putative Cellular Receptor Of Gp41

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion.

Helical Interactions in the HIV-1 Gp41 Core Reveal Structural Basis for the Inhibitory Activity of Gp41 Peptides.

Residues in the Gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by Gp120-Directed Inhibitors.

Identification Of A Critical Motif For The Human Immunodeficiency Virus Type 1 (Hiv-1) Gp41 Core Structure: Implications For Designing Novel Anti-Hiv Fusion Inhibitors

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.

Critical Amino Acids Within the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein V4 N- and C-terminals Contribute to Virus Entry.

Development Of Small-Molecule Hiv Entry Inhibitors Specifically Targeting Gp120 Or Gp41

Subunit Organization of the Membrane-Bound HIV-1 Envelope Glycoprotein Trimer

Molecular Architecture of the Uncleaved HIV-1 Envelope Glycoprotein Trimer

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

Molecular Motions of Human HIV-1 Gp120 Envelope Glycoproteins

Structure and Immune Recognition of Trimeric Pre-Fusion HIV-1 Env.

Structural Characteristics and Biological Functions of the HIV-1 Gp120 V3 Region

HIV-1 Gp41 and Type I Interferon: Sequence Homology and Biological As Well As Clinical Implications.